American Journal Of Cardiovascular Drugs

Journal Title：American Journal Of Cardiovascular Drugs

Promoting rational therapy within the discipline of cardiology, the American Journal of Cardiovascular Drugs covers all aspects of the treatment of cardiovascular disorders, particularly the place in therapy of newer and established agents.

Via a program of reviews and original clinical research articles, the journal addresses major issues relating to treatment of these disorders, including the pharmacology, efficacy and adverse effects of the major classes of drugs; information on newly developed drugs and drug classes; the therapeutic implications of latest research into the aetiology of cardiovascular disorders; and the practical management of specific clinical situations.

The American Journal of Cardiovascular Drugs offers a range of additional enhanced features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by a Key Points summary, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist patients, caregivers and others in understanding important medical advances. The journal also provides the option to include various other types of enhanced features including slide sets, videos and animations. All enhanced features are peer reviewed to the same high standard as the article itself. Peer review is conducted using Editorial Manager®, supported by a database of international experts. This database is shared with other Adis journals.

《美国心血管药物杂志》旨在促进心脏病学领域的合理治疗，涵盖了心血管疾病治疗的各个方面，特别是新药和成熟药物在治疗中的作用。

通过一系列评论和原创临床研究文章，该杂志探讨了与这些疾病治疗相关的主要问题，包括主要药物类别的药理学、疗效和不良反应；新开发药物和药物类别的信息；心血管疾病病因学最新研究的治疗意义；以及特定临床情况的实际管理。

《美国心血管药物杂志》提供了一系列额外的增强功能，旨在提高杂志内容的可见性、读者群和教育价值。每篇文章都附有要点摘要，为广大读者提供内容的省时概述。文章可能附有通俗易懂的语言摘要，以帮助患者、护理人员和其他人了解重要的医学进展。该杂志还提供包括幻灯片集、视频和动画等各种其他类型的增强功能的选项。所有增强功能都经过同行评审，标准与文章本身一样高。同行评审使用 Editorial Manager® 进行，由国际专家数据库支持。该数据库与其他 Adis 期刊共享。

American Journal Of Cardiovascular Drugs创刊于2001年，由Springer International Publishing出版商出版，收稿方向涵盖医学 - 心血管系统全领域，此期刊水平偏中等偏靠后，在所属细分领域中专业影响力一般，过审相对较易，如果您文章质量佳，选择此期刊，发表机率较高。平均审稿速度 12周，或约稿 ，影响因子指数2.8，该期刊近期没有被列入国际期刊预警名单，广大学者值得一试。